Lantern Pharma Inc (LTRN)

08:09 AM

Lantern Pharma reports complete response in aggressive lymphoma patient - Investing.com

08:09 AM

07:56 AM

Lantern Pharma Reports Complete Response in Heavily Pre-Treated Lymphoma Patient with LP-284 in Phase 1 Clinical Trial - Business Wire

07:56 AM

Jul 22, 2025

What drives Lantern Pharma Inc. stock priceFree Stock Market Forecast Reports - Autocar Professional

Jul 22, 2025

Jul 22, 2025

What analysts say about Lantern Pharma Inc. stockTremendous gains - jammulinksnews.com

Jul 22, 2025

Jul 22, 2025

Is Lantern Pharma Inc. a good long term investmentTriple-digit returns - jammulinksnews.com

Jul 22, 2025

Jul 22, 2025

Lantern Pharma Inc. Stock Analysis and ForecastBreakthrough capital growth - jammulinksnews.com

Jul 22, 2025

Jul 22, 2025

Lantern Pharma (NASDAQ: LTRN) Secures EU Patent For AI-Designed Cancer Drug LP-284 - Barchart.com

Jul 22, 2025

Jul 21, 2025

Lantern Pharma (LTRN) Secures EU Patent for Cancer Drug LP-284 - GuruFocus

Jul 21, 2025

Jul 21, 2025

Lantern Pharma secures EU patent for AI-driven cancer drug LP-284 - MSN

Jul 21, 2025

Jul 21, 2025

Lantern Pharma Secures EU Patent Allowance for LP-284, Bolstering Global IP Position for AI-Developed Cancer Therapy - BioSpace

Jul 21, 2025

Jul 21, 2025

Lantern Pharma (LTRN) Gains Patent Approval for Key Drug in Euro - GuruFocus

Jul 21, 2025

Jul 17, 2025

Lantern Pharma Unveils AI Module for Predicting Cancer Treatment Efficacy - AInvest

Jul 17, 2025

Jul 16, 2025

Lantern Pharma (NASDAQ: LTRN) Launches AI Module to Accelerate Development of Targeted Cancer Combination Therapies - The Globe and Mail

Jul 16, 2025

Jul 16, 2025

IBN Initiates Coverage of Lantern Pharma Inc. - GlobeNewswire

Jul 16, 2025

Jul 16, 2025

Lantern Pharma Initiates Coverage with IBN, Aims to Revolutionize Oncology Drug Development - AInvest

Jul 16, 2025

Jul 15, 2025

Why Lantern Pharma Inc. stock attracts strong analyst attentionFree Stock Movement Tracking - Newser

Jul 15, 2025

Jul 15, 2025

How Lantern Pharma Inc. stock performs during market volatilityInvestor Friendly Risk Reward - Newser

Jul 15, 2025

Jul 15, 2025

Lantern Pharma Inc. Unveils AI-Powered Module to Predict Activity and Efficacy of Combination Regimens in Clinical Cancer Treatment - MarketScreener

Jul 15, 2025

Jul 15, 2025

Lantern Pharma launches AI module to predict cancer treatment combos - Investing.com India

Jul 15, 2025

Jul 15, 2025

Lantern Pharma (LTRN) Launches AI Module for Cancer Treatment Ad - GuruFocus

Jul 15, 2025

Jul 15, 2025

Lantern Pharma launches AI module to predict cancer treatment combos By Investing.com - Investing.com South Africa

Jul 15, 2025

Jul 15, 2025

Lantern Pharma Unveils Groundbreaking AI-Powered Module to Predict Activity and Efficacy of Combination Regimens in Clinical Cancer Treatment - Business Wire

Jul 15, 2025

Jul 15, 2025

What makes Lantern Pharma Inc. stock price move sharplyFree Access to Community - Newser

Jul 15, 2025

Jul 08, 2025

LTRN Stock Price and Chart — NASDAQ:LTRN - TradingView

Jul 08, 2025

Jul 03, 2025

Lantern Pharma Enters ATM Sales Agreement with ThinkEquity - TipRanks

Jul 03, 2025

Jul 01, 2025

Why Lantern Pharma (NASDAQ: LTRN) Is ‘One to Watch’ - The Globe and Mail

Jul 01, 2025

Jul 01, 2025

Why Lantern Pharma (NASDAQ: LTRN) Is ‘One To Watch’ - Barchart.com

Jul 01, 2025

Jun 30, 2025

Lantern Pharma Inc. Harnesses AI to Revolutionize Oncology Drug Development - citybuzz -

Jun 30, 2025

Jun 27, 2025

Lantern Pharma’s (NASDAQ: LTRN) AI-Powered Platform Delivers Promising and Durable Results in Lung Cancer Trial - Barchart.com

Jun 27, 2025

Jun 17, 2025

Lantern Pharma (NASDAQ: LTRN) Reports Complete Response in Advanced NSCLC Patient in HARMONIC(TM) Trial - The Globe and Mail

Jun 17, 2025

Jun 17, 2025

Lantern Pharma Inc. Reports Complete Response in Advanced NSCLC Patient in HARMONIC(TM) Trial - citybuzz -

Jun 17, 2025